Riluzole Dosing in HD (RID-HD)

The Riluzole Dosing in HD (RID-HD) study is designed to access riluzole’s short term impact on motor, cognitive and behavioral symptoms of HD and to gather information on the safety and tolerability of Riluzole.

The RID-HD study is currently enrolling subjects who have early HD at sites in the US and Canada.

To learn more about the RID-HD study and the participating HSG site nearest you please contact the HSG at their toll free number: 1-800-487-7671. Or the HSG website at: www.Huntington-Study-Group.org